Characterization of a small molecule that promotes cell cycle activation of human induced pluripotent stem cell-derived cardiomyocytes - PubMed (original) (raw)

Characterization of a small molecule that promotes cell cycle activation of human induced pluripotent stem cell-derived cardiomyocytes

Masamichi Ito et al. J Mol Cell Cardiol. 2019 Mar.

Free article

Abstract

Background: Since regenerative capacity of adult mammalian myocardium is limited, activation of the endogenous proliferative capacity of existing cardiomyocytes is a potential therapeutic strategy for treating heart diseases accompanied by cardiomyocyte loss. Recently, we performed a compound screening and developed a new drug named TT-10 (C11H10FN3OS2) which promotes the proliferation of murine cardiomyocytes via enhancement of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity and improves cardiac function after myocardial infarction in adult mice.

Methods and results: To test whether TT-10 can also promote the proliferative capacity of human cardiomyocytes, we investigated the efficacy of TT-10 on human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSCMs). The hiPSCs were established from monocytes obtained from healthy donors and cardiac differentiation was performed using a chemically defined protocol. As was observed in murine cardiomyocytes, TT-10 markedly promoted cell cycle activation and increased cell division of hiPSCMs. We then evaluated other effects of TT-10 on the functional properties of hiPSCMs by gene expression and cell motion analyses. We observed that TT-10 had no unfavorable effects on the expression of functional and structural genes or the contractile properties of hiPSCMs.

Conclusions: Our results suggest that the novel drug TT-10 effectively activated the cell cycle of hiPSCMs without apparent functional impairment of myocardium, suggesting the potential of clinical usefulness of this drug.

Keywords: Cell cycle activation; Hippo pathway; Induced pluripotent stem cell-derived cardiomyocyte; Regeneration; Regenerative medicine; Small molecule.

PubMed Disclaimer

Cited by

Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
Yang H, Yang Y, Kiskin FN, Shen M, Zhang JZ. Yang H, et al. Stem Cell Res Ther. 2023 Aug 30;14(1):228. doi: 10.1186/s13287-023-03470-w. Stem Cell Res Ther. 2023. PMID: 37649113 Free PMC article. Review.
Phenotypic technologies in stem cell biology.
Vandana JJ, Lacko LA, Chen S. Vandana JJ, et al. Cell Chem Biol. 2021 Mar 18;28(3):257-270. doi: 10.1016/j.chembiol.2021.02.001. Epub 2021 Mar 1. Cell Chem Biol. 2021. PMID: 33651977 Free PMC article. Review.
Some Insights into the Regulation of Cardiac Physiology and Pathology by the Hippo Pathway.
Ramaccini D, Pedriali G, Perrone M, Bouhamida E, Modesti L, Wieckowski MR, Giorgi C, Pinton P, Morciano G. Ramaccini D, et al. Biomedicines. 2022 Mar 21;10(3):726. doi: 10.3390/biomedicines10030726. Biomedicines. 2022. PMID: 35327528 Free PMC article. Review.
Stimulation of Cardiomyocyte Proliferation Is Dependent on Species and Level of Maturation.
Yücel D, Garay BI, Perlingeiro RCR, van Berlo JH. Yücel D, et al. Front Cell Dev Biol. 2022 May 19;10:806564. doi: 10.3389/fcell.2022.806564. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35663393 Free PMC article.
TEAD1 trapping by the Q353R-Lamin A/C causes dilated cardiomyopathy.
Yamada S, Ko T, Ito M, Sassa T, Nomura S, Okuma H, Sato M, Imasaki T, Kikkawa S, Zhang B, Yamada T, Seki Y, Fujita K, Katoh M, Kubota M, Hatsuse S, Katagiri M, Hayashi H, Hamano M, Takeda N, Morita H, Takada S, Toyoda M, Uchiyama M, Ikeuchi M, Toyooka K, Umezawa A, Yamanishi Y, Nitta R, Aburatani H, Komuro I. Yamada S, et al. Sci Adv. 2023 Apr 14;9(15):eade7047. doi: 10.1126/sciadv.ade7047. Epub 2023 Apr 14. Sci Adv. 2023. PMID: 37058558 Free PMC article.

Characterization of a small molecule that promotes cell cycle activation of human induced pluripotent stem cell-derived cardiomyocytes - PubMed (original) (raw)